Prof. Bilezikiandi of New York explained this important, innovative technique.
The central problem linked to replacement therapy is adequate management of
calcium and Vitamin D dosage, and this is not always an easy goal to attain.
How much Vitamin D need we administer to these patient for adequate control
of calcemia and what is the
price they pay? How can we
counteract the negative effects
of this replacement therapy on
bone metabolism? How can we
maintain quality of life at ac-
ceptable levels? According to
Prof. Bilezikian, the real problem is that patients af-
fected with hypoparathyroidism often receive exces-
sively high or insufficient doses of calcium and Vita-
min D and, in both cases, the outcome for their
health can be serious. Hypoparathyroidism is the only specific hormonal deficit disorder not currently
treatable via a well-defined hormone replacement therapy. Or at least this was true until today, since
in January 2015 the FDA approved marketing of a new releasing hormone denominated rhPTH (1-84)
for use in treatment of patients with hypoparathyroidism.
Fondazione
Internazionale
Menarini
To find answers to these and other interesting queries and for more in-depth in-
formation, go to egister at the site to access the
multimedia material.
John P. Bilezikian
New York - USA
Replacement therapy with PTH peptides
What data have been published on this new treatment adjunct? - - - What is its ef-
fect on bone metabolism? - - - What is its effect on calcemia? - - - And on quality
of life?